Back HIV/AIDS

HIV / AIDS

New HIV NNRTI Lersivirine Matches Efavirenz in Phase 2b Trial

The investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) lersivirine suppressed HIV viral load as well as efavirenz (Sustiva) in a 48-week trial, but with a different and side effect profile, researchers reported in the February 1, 2013, Journal of Acquired Immune Deficiency Syndromes.

alt

Low-Level HIV Viral Load Linked to Gut Leakage and Inflammation

Even low levels of HIV in the body are associated with microbial translocation, or leakage of bacteria from the gut, which can lead to excessive immune activation and inflammation, according to study published in the February 1, 2013, Journal of Acquired Immune Deficiency Syndromes

alt

Complera Label Adds Low Viral Load Restriction, Liver Toxicity Warning

The U.S. Food and Drug Administration (FDA) last week approved revised label information for Complera, Gilead Sciences' tenofovir/emtricitabine/rilpivirine single-tablet regimen. Among the changes, the updated label clarifies that this regimen is indicated for previously untreated people with low baseline viral load, as those with higher levels were more likely to experience treatment failure in clinical trials.

alt

Gilead Starts Phase 3 Trials for New HIV Pro-drug Tenofovir Alafenamide

Gilead Sciences announced last week that its new single-tablet regimen containing tenofovir alafenamide fumarate  (TAF) -- a pro-drug of the widely used tenofovir disoproxil fumarate (TDF) -- has entered the final phase of pre-approval clinical testing.

alt

Pediatrics Association Recommends Bottle Feeding for Babies of HIV+ Mothers

HIV positive women in high-income countries where clean water and safe baby formula are widely available should avoid breast-feeding -- regardless of antiretroviral therapy (ART) use or low viral load -- in order to minimize the risk of transmitting the virus to their infants, according to a new policy statement from the American Academy of Pediatrics.

alt

Drug Overdose Is Leading Cause of Death for Homeless People in Boston

The mortality rate among homeless people in Boston has remained steady over the past 2 decades, but drug overdose has overtaken HIV as a leading cause of death, researchers reported in the January 14, 2013, advance edition of JAMA Internal Medicine.

alt

Can Low Volume Syringes Help End HIV and HCV Transmission Among People Who Use Drugs?

Syringes that have a lower "dead space" volume retain less fluid that can harbor HIV and hepatitis C virus (HCV), and switching to this type could help reduce viral transmission among injection drug users, according to an article in the January 2013 issue of International Journal of Drug Policy.

alt